Related Experiment Video

Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients

Aaron M Harris1, Alexander J Millman1, Meredith Lora2

  • 1Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Vaccine
|March 24, 2019
PubMed

Insights

Hepatitis B virus (HBV) testing and vaccination are suboptimal in hepatitis C virus (HCV) patients, despite high HBV prevalence. Improved strategies are needed for HBV screening, care linkage, and vaccination in this population.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis B virus (HBV) testing is crucial for co-infected patients with hepatitis C virus (HCV).
  • Current HBV testing and vaccination rates in HCV-infected individuals are suboptimal.
  • This study addresses the need for improved HBV management in HCV patients.

Purpose of the Study:

  • To determine the prevalence of hepatitis B testing, care linkage, and vaccination in HCV patients.
  • To identify gaps in HBV screening and management within a safety-net health system.
  • To inform strategies for enhancing HBV care for HCV-infected individuals.

Main Methods:

  • Retrospective cohort analysis of HCV-infected patients from 2004-2016.
  • Utilized electronic health record data from Grady Health System.
  • Assessed prevalence of HBV serological markers (HBsAg, anti-HBc, anti-HBs), HBV DNA/HBeAg testing, and HBV vaccination.

Main Results:

  • 86% of HCV patients had HBsAg test results; 1.2% were HBsAg-positive.
  • Among those with complete HBV serology, 27% were HBV-susceptible.
  • Only 50% of HBV-susceptible patients received at least one dose of the HBV vaccine; linkage to care for HBsAg-positive patients was also limited.

Conclusions:

  • A significant proportion of HCV patients have current or past HBV infection.
  • Gaps exist in comprehensive HBV testing, care linkage, and vaccination for HCV patients.
  • Enhanced strategies are required to improve HBV screening, care, and vaccination uptake in this population.
Abstract

Keywords:
Hepatitis BHepatitis CRegistryTestingVaccination

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.6K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
222
Phosphodiester Linkages01:01

Phosphodiester Linkages

Overview
Phosphodiester bond forms when a phosphoric acid molecule (H3PO4) links with two hydroxyl groups (–OH) of two other molecules, forming two ester bonds. Two water molecules are released in this process. The phosphodiester bond is commonly found in nucleic acids (DNA and RNA) and plays a critical role in their structure and function.
Phosphodiester Bonds Link Nucleotides Together
DNA and RNA are polynucleotides or long chains of nucleotides that are linked together. A nucleotide is...
110.8K
Vaccinations01:51

Vaccinations

Overview
51.3K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K